Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
90Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-105.43M | $-2.31 |
| 2024 | $0.00 | $-83.72M | $-4.99 |
| 2023 | $0.00 | $-5.34M | $-4.44 |
| 2022 | $0.00 | $-9.93M | $-8.27 |
| 2021 | $0.00 | $-19.32M | $-16.68 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.59 per share
Typical surprise +12.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.55 vs $-0.51miss
- Wed, May 13$-0.48 vs $-0.55beat
- Thu, Mar 12$-0.45 vs $-0.61beat
- Wed, Nov 12$-0.55 vs $-0.56beat
- Mon, Aug 11$-0.46 vs $-0.48beat
- Wed, May 14$-0.40 vs $-0.57beat
Estimates and results for ORKA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ORKAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- News (RSS)seekingalpha·4d ago·Negative
Oruka Therapeutics GAAP EPS of -$0.55 misses by $0.01
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026 Phase 3 program for ORKA-001 expected to begin in 1H 2027 ORCA-SURGE Week 16 data accelerated, now expected in 1Q 2027 ORCA-SPLASH, a Phase 2 trial of ORKA-002 in moderate-to-severe hidradenitis suppura
View source ↗